Alkermes PLC
Fermé
SecteurSoins de santé
44.26 -1.45
Résumé
Variation du prix de l'action
24h
Min
44.12
Max
44.64
Revenu | -116M -66M |
|---|---|
Ventes | 8.4M 393M |
P/E Moyenne du Secteur | 47.167 49.052 |
BPA | 0.38 |
Marge bénéficiaire | -16.92 |
Employés | 2,050 |
EBITDA | -98M -22M |
Recommandations | Achat Fort |
|---|---|
Prévisions sur 12 Mois | +6.59% upside |
Prochains Résultats | 28 juil. 2026 |
|---|
Capitalisation Boursière | 1.4B 7.1B |
|---|---|
Ouverture précédente | 45.71 |
Clôture précédente | 44.26 |
Sentiment de l'Actualité
By Acuity
100%
0%
330 / 342 Classement par Healthcare
Alkermes PLC Graphique
Les performances passées ne sont pas un indicateur fiable des résultats futurs.
À Propos Alkermes PLC
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
